about
Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systemsAntivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRIAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsVascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesisTubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenograftsLow-pressure pulsed focused ultrasound with microbubbles promotes an anticancer immunological response.Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapyAngiostatic treatment of neuroblastoma.In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts.Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.Angiogenesis inhibitors and radiotherapy of primary tumours.Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectinsIdentification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenograftsAngiogenesis in the uterus: potential regulation and relation to tumor angiogenesis.Vascular targeting agents.Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.Characterizing the tumor response to treatment with combretastatin A4 phosphate.A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in miceVascular-targeted cancer gene therapy.Genistein, a dietary-derived inhibitor of in vitro angiogenesisThe response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation.Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hopeTumor vasculature as target for therapeutic intervention.Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.Vascular-disrupting agents in oncology.Tubulin inhibitors: a patent review.Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta.Early investigational tubulin inhibitors as novel cancer therapeutics.Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.Tumor vascular infarction: prospects and challenges.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.
P2860
Q26798467-8CD46A4C-9E8F-4ADD-A0E3-CEC51A2AA28CQ28268126-6AB9C9C9-DC15-4653-A025-A3CC3076BBA9Q28270261-0A482A6B-8D3F-460F-A75E-8E0A98AAAC0CQ28300434-A20AC004-6A68-4117-A08C-A6EFCFDE119EQ28482576-E6C3E055-F945-4D47-92EC-A26E740C396CQ30459141-41D879CE-B140-4224-A63E-E6E2744E8260Q30835449-2F9A68B0-8DDA-42B7-9BDC-5B4EF934CF4DQ33501372-61DAD59B-9F7D-4A07-8DB9-71D85A9D5FF1Q33664081-CA87F50A-2305-49B8-83A9-98EEBD87941CQ33827707-991B1DD8-F88E-4CF1-8F38-51A3F9714D18Q33863907-92717AB7-79D2-45AF-9F9D-CBF73E12692FQ34603062-1CC5BFB7-FE73-4B20-A376-0F8B1140885FQ34701364-C63B8B3C-9AF8-4223-9E9D-8060788E4B75Q34765825-6E96EB63-D9F9-4F71-B1BB-242097DF7D3BQ35030421-44A9149D-5769-4F1E-9A87-CB6071EABEFDQ35043106-47A95B80-DB7A-467D-A5C0-278703BA5332Q35082693-96D6F27C-2878-47F9-95F1-E2066C511939Q35343246-F4132609-DA74-4A70-95D7-BC5078479D03Q35642613-1D3904D6-78EF-46EA-B8A7-F92EFBDA0C50Q35774179-5FE2BF4F-10EB-44B1-B9AA-6F81986128CCQ35793182-6B060648-6A9A-4F9A-8BC0-7AA40038CD80Q35833173-C2B98106-A28F-4571-B07E-822402973A77Q35967282-27F11D89-0417-4511-8CA0-73C9398AC523Q36192742-0F478439-4350-40AB-A667-8A3739D3454AQ36292417-1085852B-0326-4C46-BE08-71C0BB6B4449Q36379734-95D611A9-C8F2-4640-ABBB-B5AE805162BFQ36566561-96EF7330-CEBA-44B1-B245-CA5B602CD779Q36696611-FB332120-838E-4F31-998A-291D45A6F7FDQ36884230-392A356D-1C73-4FA8-8D2E-A1F1948475F4Q37800110-743F2D97-561D-4038-AB0F-615A309BEFAEQ37979314-BD542DD1-1E93-436E-9560-C23E5088130BQ38073812-C9D93C88-9AE2-4B2D-8B9E-5EAB040FAEBFQ38169237-4D873E53-ADA9-4347-BF36-2965C5996A95Q38349912-71362CB1-F001-4D01-915A-B5DDC3470FCCQ38836161-83A91836-456B-466F-A1B6-5A242AE9FD20Q38858806-F5D0DF8E-6845-4779-AD95-06BC319ADE99Q39065317-8B899B8D-793F-46A5-9A54-05D6689FDCD9Q39205186-4B0F421F-624E-4A4D-9954-5A73F41AF0AFQ39432031-A9AF58E8-54CF-4E7B-8549-C3D8EC8F3218Q39594713-146803F9-7C64-482D-9C8E-99337AD3CDC6
P2860
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Vascular attack as a therapeutic strategy for cancer.
@en
type
label
Vascular attack as a therapeutic strategy for cancer.
@en
prefLabel
Vascular attack as a therapeutic strategy for cancer.
@en
P356
P1476
Vascular attack as a therapeutic strategy for cancer.
@en
P2093
J Denekamp
P2888
P304
P356
10.1007/BF00046365
P577
1990-11-01T00:00:00Z
P6179
1016305456